Cargando…

GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer

BACKGROUND: Basal-like breast cancer (BLBC) takes up about 10–20% of all breast cancer(BC), what’s more, BLBC has the lowest survival rate among all BC subtypes because of lacks of efficient treatment methods. We aimed to explore the molecules that can be used as diagnostic maker for BLBC at early s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Liang, Zhang, Yue, Zheng, Chunlei, Zhao, Fuqiang, Lin, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386636/
https://www.ncbi.nlm.nih.gov/pubmed/37507701
http://dx.doi.org/10.1186/s12905-023-02547-1
_version_ 1785081716702969856
author Wu, Liang
Zhang, Yue
Zheng, Chunlei
Zhao, Fuqiang
Lin, Yan
author_facet Wu, Liang
Zhang, Yue
Zheng, Chunlei
Zhao, Fuqiang
Lin, Yan
author_sort Wu, Liang
collection PubMed
description BACKGROUND: Basal-like breast cancer (BLBC) takes up about 10–20% of all breast cancer(BC), what’s more, BLBC has the lowest survival rate among all BC subtypes because of lacks of efficient treatment methods. We aimed to explore the molecules that can be used as diagnostic maker for BLBC at early stage and provide optimized treatment strategies for BLBC patients in this study. METHODS: Apply weighted gene co-expression network analysis (WGCNA) to identify gene modules related to BLBC;The functional enrichment of candidate genes related to BLBC in the red module of Go data package and KEGG analysis;Overlapping cross analysis of URGs and WGCNA to identify candidate genes in each BC subtype;Divide BCBL patients into high-risk and low-risk groups, and analyze the two groups of overall survival (OS) and relapse free survival (RFS);Screening of GEMIN4 dependent cell lines; QRT PCR was used to verify the expression of GEMIN4 transfected with siRNA; CCK8 was used to determine the effect of GEMIN4 on cell viability; Positive cell count detected by BrdU staining;GO and KEGG enrichment analysis of GEMIN4. RESULTS: The "red module" has the highest correlation with BLBC, with 913 promising candidate genes identified from the red module;913 red module candidate genes related to BLBC participated in multiple GO terms, and KEGG enrichment analysis results mainly enriched in estrogen signaling pathways and pathways in cancer;There are 386 overlapping candidate genes among the 913 "red module" genes identified by 1893 common URG and WGCNA;In BLBC patients, 9 highly expressed genes are associated with OS. Five highly expressed genes are associated with RFS. Kaplan Meier survival analysis suggests that high GEMIN4 expression levels are associated with poor prognosis in BLBC patients;The GEMIN4 gene dependency score in HCC1143 and CAL120 cell lines is negative and low; Si-GEMIN4-1 can significantly reduce the mRNA expression of GEMIN4; Si-GEMIN4 can inhibit cell viability; Si-GEMIN4 can reduce the number of positive cells;GO enrichment analysis showed that GEMIN4 is associated with DNA metabolism processes and adenylate binding; KEGG pathway enrichment analysis shows that GEMIN4 is related to ribosome biogenesis in eukaryotes. CONCLUSION: We hypothesized that GEMIN4 may be the potential target for the treatment of BLBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-023-02547-1.
format Online
Article
Text
id pubmed-10386636
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103866362023-07-30 GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer Wu, Liang Zhang, Yue Zheng, Chunlei Zhao, Fuqiang Lin, Yan BMC Womens Health Research Article BACKGROUND: Basal-like breast cancer (BLBC) takes up about 10–20% of all breast cancer(BC), what’s more, BLBC has the lowest survival rate among all BC subtypes because of lacks of efficient treatment methods. We aimed to explore the molecules that can be used as diagnostic maker for BLBC at early stage and provide optimized treatment strategies for BLBC patients in this study. METHODS: Apply weighted gene co-expression network analysis (WGCNA) to identify gene modules related to BLBC;The functional enrichment of candidate genes related to BLBC in the red module of Go data package and KEGG analysis;Overlapping cross analysis of URGs and WGCNA to identify candidate genes in each BC subtype;Divide BCBL patients into high-risk and low-risk groups, and analyze the two groups of overall survival (OS) and relapse free survival (RFS);Screening of GEMIN4 dependent cell lines; QRT PCR was used to verify the expression of GEMIN4 transfected with siRNA; CCK8 was used to determine the effect of GEMIN4 on cell viability; Positive cell count detected by BrdU staining;GO and KEGG enrichment analysis of GEMIN4. RESULTS: The "red module" has the highest correlation with BLBC, with 913 promising candidate genes identified from the red module;913 red module candidate genes related to BLBC participated in multiple GO terms, and KEGG enrichment analysis results mainly enriched in estrogen signaling pathways and pathways in cancer;There are 386 overlapping candidate genes among the 913 "red module" genes identified by 1893 common URG and WGCNA;In BLBC patients, 9 highly expressed genes are associated with OS. Five highly expressed genes are associated with RFS. Kaplan Meier survival analysis suggests that high GEMIN4 expression levels are associated with poor prognosis in BLBC patients;The GEMIN4 gene dependency score in HCC1143 and CAL120 cell lines is negative and low; Si-GEMIN4-1 can significantly reduce the mRNA expression of GEMIN4; Si-GEMIN4 can inhibit cell viability; Si-GEMIN4 can reduce the number of positive cells;GO enrichment analysis showed that GEMIN4 is associated with DNA metabolism processes and adenylate binding; KEGG pathway enrichment analysis shows that GEMIN4 is related to ribosome biogenesis in eukaryotes. CONCLUSION: We hypothesized that GEMIN4 may be the potential target for the treatment of BLBC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12905-023-02547-1. BioMed Central 2023-07-28 /pmc/articles/PMC10386636/ /pubmed/37507701 http://dx.doi.org/10.1186/s12905-023-02547-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Wu, Liang
Zhang, Yue
Zheng, Chunlei
Zhao, Fuqiang
Lin, Yan
GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title_full GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title_fullStr GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title_full_unstemmed GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title_short GEMIN4, a potential therapeutic targets for patients with basal-like subtype breast cancer
title_sort gemin4, a potential therapeutic targets for patients with basal-like subtype breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386636/
https://www.ncbi.nlm.nih.gov/pubmed/37507701
http://dx.doi.org/10.1186/s12905-023-02547-1
work_keys_str_mv AT wuliang gemin4apotentialtherapeutictargetsforpatientswithbasallikesubtypebreastcancer
AT zhangyue gemin4apotentialtherapeutictargetsforpatientswithbasallikesubtypebreastcancer
AT zhengchunlei gemin4apotentialtherapeutictargetsforpatientswithbasallikesubtypebreastcancer
AT zhaofuqiang gemin4apotentialtherapeutictargetsforpatientswithbasallikesubtypebreastcancer
AT linyan gemin4apotentialtherapeutictargetsforpatientswithbasallikesubtypebreastcancer